The company recently unveiled an ambitious long-term growth plan targeting 2030 and issued 2026 revenue guidance of $4.9-$5.3 billion, implying significant year-over-year growth. Management emphasized its goal to become the revenue leader in transthyretin amyloidosis and stated the company is on the verge of profitability. Despite a recent share price decline over the past week and month, the stock has delivered strong long-term returns of over 119% in five years, supported by a full pipeline in RNAi therapies.